Search Results
May 21, 2026, 17:00 ET Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
patient stratification across multiple cancer types.The five presentations include studies across biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), microsatellite-stable (MSS), metastatic colorectal cancer and advanced gastric cancer (AGC).One
More news about: Lunit
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
Results from the first Phase I study in China of BL-M14D1, a novel DLL3 directed ADC, in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumorsSafety and efficacy results from a Phase II study in China evaluating
More news about: SystImmune, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
the first clinical results for an investigational ADC targeting Nectin-4 in patients with advanced urothelial carcinoma and data from programs across lung, breast and blood cancers INDIANAPOLIS, May 21, 2026 /PRNewswire/
More news about: Eli Lilly and Company
May 21, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares
More news about: TransMedics Group, Inc.
May 21, 2026, 15:25 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
May 21, 2026, 14:41 ET Open Source Imaging Consortium (OSIC) and the Baillie Gifford Pandemic Science Hub at the University of Edinburgh Announce Project Cairn
therapies."Project Cairn will initially focus on early lung disease, including interstitial lung abnormalities (ILA) and their progression to interstitial lung disease (ILD), with plans to expand over time to include additional rare lung diseases.
More news about: Open Source Imaging Consortium (OSIC)
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as non-small cell lung cancer (NSCLC), breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique,
More news about: Kelun-Biotech
May 21, 2026, 08:47 ET FDA Veteran Paz Vellanki, MD, PhD, Joins Precision for Medicine, Forming a Trio of Former Regulatory Leaders
Division of Oncology 2 at the U.S. Food and Drug Administration (FDA), where she oversaw drug development and regulatory decisions for therapeutics in lung cancer, head and neck cancer and rare tumors and molecular subsets of cancers. In her new role, Dr. Vellanki will partner with life sciences companies
More news about: Precision for Medicine
May 20, 2026, 09:26 ET Brayton Purcell LLP Highlights NPR Report and Broadcast Warning of Nationwide Silicosis Crisis
urgent attention to a growing occupational health crisis following a May 18, 2026 report by NPR science correspondent Nell Greenfieldboyce examining lung disease among U.S. countertop workers.
More news about: Brayton Purcell LLP
May 20, 2026, 09:00 ET Mercy Hospice Brings Comfort to Patients, Families in Most Difficult Times
ST. LOUIS, May 20, 2026 /PRNewswire/ -- When Jerry Frederiksen's stepmother was diagnosed with stage 4 lung cancer, he knew end-of-life care was the next step, but he had no idea what that meant or what he needed to do.
More news about: Mercy
May 20, 2026, 09:00 ET IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
management's repeated assurances about TACTI-004's trajectory. Throughout the Class Period, the lawsuit contends, the Company described its pivotal Phase III lung cancer trial as exhibiting "strong operational progress" and highlighted enrollment milestones, investigator enthusiasm, and FDA regulatory clearance.
More news about: Levi & Korsinsky, LLP
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
Type & DetailsLung CancerKEYNOTE-495/KeyImPaCT
More news about: Eisai Inc.
May 20, 2026, 01:54 ET AstraZeneca dan Roche Diagnostics Asia Pacific Pacific Perkuat Pengembangan Patologi Digital Berbasis AI untuk Kanker Payudara dan Paru
tingkat HER2[3] yang rendah. Sementara itu, biomarker TROP2 ditemukan pada 82-90% kasus kanker paru non-sel kecil (non-small cell lung cancer/NSCLC)[4]. Kondisi ini menunjukkan pentingnya pengujian biomarker yang presisi untukmenentukan terapi yang paling tepat bagi pasien.
More news about: AstraZeneca
May 20, 2026, 01:51 ET स्तन तथा फेफड़ों के कैंसर में एडवांस पैथोलॉजी के लिए एक स्थायी इकोसिस्टम को गति देने में सहायता करने के लिए AstraZeneca ने Roche Diagnostics Asia Pacific के साथ सहयोग किया
https://biopharma-asia.com/sections/roche-granted-fda-breakthrough-device-designation-for-ai-driven-companion-diagnostic-for-non-small-cell-lung-cancer/
More news about: AstraZeneca
May 19, 2026, 20:00 ET Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
May 19, 2026, 16:05 ET TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday,
More news about: TransMedics Group, Inc.
May 19, 2026, 14:51 ET Altesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026
small airway lung function compared to placeboORLANDO, Fla., May 19, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases
More news about: Altesa Biosciences Inc.
May 19, 2026, 11:30 ET Portable Ultrasound Scanner Market Size to Hit USD 4.1 Billion, by 2032 at 5.7% CAGR: Allied Market Research
ultrasound imaging within previously underserved, clinical environments. The COVID-19 pandemic demand for portable ultrasound particularly for lung assessment and as a bedside monitoring tool but also COVID-19 disease progression without the need to transport potentially infected patients has raised
More news about: Allied Market Research
May 19, 2026, 10:00 ET Hearst Magazines Hosts 3rd Annual Women's Health Lab in Partnership With Northwell's Katz Institute for Women's Health
MD.Beyond the Scars: Navigating Life with Interstitial Lung Disease – Prevention Executive Editor Stephanie Dolgoff guided a discussion centered on the emotional and physical toll of progressive lung disease, including the challenges of delayed diagnosis, the importance
More news about: Hearst Magazines
May 19, 2026, 09:49 ET Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 19, 2026 /PRNewswire/ -- AlphaDetect,
More news about: Alpha-1 Foundation
May 19, 2026, 09:30 ET Funding from Patients, Caregivers, Foundations and Industry Partners Fuels ALK-positive Research
for people living with ALK-positive lung cancer. Leading the fundraising effort was Colleen Conner Ziegler, chair of LCRF's board of directors and ALK-positive lung cancer survivor, the Murgatroyd family, who lost their daughter at the age of 24 to ALK-positive lung cancer, David Cornbrooks, co-founder
More news about: Lung Cancer Research Foundation
May 19, 2026, 09:03 ET Azra AI Appoints Oncology Leader Jessica Turgon to Board of Directors
multimodal data integration, and workflow automation, Azra transforms fragmented clinical data into actionable intelligence — powering solutions across lung and breast cancer screening, incidental findings, multidisciplinary meetings, enterprise patient management and care coordination, research and clinical
More news about: Azra AI
May 19, 2026, 08:30 ET IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
May 19, 2026, 02:21 ET Implantica announces new breakthrough long-term RefluxStop® data on severe sufferers presented at DDW 2026
also included lung transplant recipients, estimated to be a few thousand per year in the U.S., representing a particularly vulnerable population because acid reflux can critically affect lung function and transplant outcomes. Dr. Borbély reported successful treatment of the first three lung transplant patients,
More news about: Implantica
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
BTC, small cell lung cancer, and ovarian cancer, thereby building a comprehensive, multi-tumor, multi-stage development layout. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across four indications: non-small cell lung cancer (NSCLC),
More news about: Nanjing Leads Biolabs Co., Ltd.